In a recent study of older patients with end-stage kidney disease living in Europe, researchers found o ne-third received an ...

Living benefits let you access your own life insurance death benefit while still alive if you qualify ...

The debate around the word “cure.” ...

Travere Therapeutics, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and ...

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing ...

Cancer cases are surging across all age groups, raising serious public health concerns in India and lifestyle changes, ...

Amid a national kidney shortage, a Bay Area priest faced years waiting for a donation. Then he found charity from an ...

The new 2026 American Heart Association (AHA) guidelines note 9 key steps to better heart health, which include more ...

SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to ...

In today's Pharmaceutical Executive Daily, AbbVie licenses a portfolio of pain compounds from China's Haisco Pharmaceutical ...

Travere Therapeutics’ sparsentan receives US FDA nod to treat focal segmental glomerulosclerosis; the first and only approved medicine for FSGS: San Diego Wednesday, April 15, 2 ...

The US Food and Drug Administration has granted full approval to Sparsentan for the treatment of Focal Segmental ...